Since 1996 WHN is the second oldest medical website on the net, second only to the American Medical Association, servicing over 35,000 physicians and scientists worldwide.
Non-Profit Trusted Source of Non-Commercial Health Information
A new release suggests promise in the peer-reviewed results of an NIH clinical trial on remdesivir plus baricitinib for treating COVID-19 that have just recently been published in the New England Journal of Medicine. The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according …
According to a press announcement the US FDA has issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). In …
The US FDA has approved the antiviral drug Veklury/Remdesivir for use in both adult and pediatric patients that are 12+ years of age and weigh at least 40kg/88lbs for the treatment of COVID-19 requiring hospitalization. However, it should only be administered in a hospital or in a healthcare setting that is capable of providing acute …
For those that may not be aware “expression of concern” is a term from medical journals to make it clear that there is good reason to believe that a paper it has published may be biased or based on erroneous data. While this statement is not always followed by retraction of the problematic article, it …
Gilead’s drug candidate Remdesivir is showing some signs of positive proof of concept in hospitalized COVID-19 patients; it outperformed placebo by 31% in a clinical trial sponsored by the NIH according to the agency. NIH’s National Institute of Allergy and Infectious Disease has released preliminary data showing the study meeting the primary outcome of statistical …